This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Galectin Therapeutics Announces Initiation Of Phase 1/2 Trial Of Novel Combination Therapy For Advanced Metastatic Melanoma

Galectin Therapeutics (NASDAQ: GALT) (“the Company”), the leader in developing carbohydrate-based therapeutic compounds to inhibit galectin proteins for the therapy of liver fibrosis and cancer, today announced that the first patient has been dosed in a Phase 1/2 trial evaluating the safety and efficacy of a novel treatment combination for the treatment of advanced metastatic melanoma. The trial, being conducted in collaboration with the Cancer Centre at the Cliniques universitaires Saint-Luc and the Ludwig Institute for Cancer Research (LICR), is evaluating Galectin Therapeutics’ carbohydrate-based galectin inhibitor compound, GM-CT-01, in combination with a Ludwig Institute peptide vaccine.

“This first-in-human Phase 1/2 study combines active vaccination and immunomodulatory agents to enhance the immune system’s ability to kill cancerous cells,” said Prof. Jean-François Baurain of the Cancer Center at the Cliniques universitaires Saint-Luc, the principal investigator of the trial. “The initiation of this trial is an important step in evaluating a potential new treatment modality for patients with advanced metastatic melanoma, who experience limited success with currently available therapies.”

“Galectin Therapeutics is committed to realizing the promise of galectin inhibition in cancer immunotherapy, and this trial of vaccine plus galectin inhibitor in metastatic melanoma is a critical first step in that effort,” commented Peter Traber, M.D., CEO of Galectin Therapeutics. “We are honored to work with Dr. Baurain and the team at the Ludwig Institute and look forward to progress in this study.”

In the Phase 1/2 study, patients will receive a peptide vaccine (either MAGE-3.A1 or NA17.A2) injection at three-week intervals throughout the study and GM-CT-01 intravenously every three days, beginning after the third dose of the peptide vaccine. Patients with at least one superficial metastatic lesion will also receive GM-CT-01 at the site of the lesion. The primary endpoint is partial or complete response.

The Cliniques universitaires Saint-Luc and LICR are funding the first stage of the trial, and the second stage will be funded through grants and/or Galectin Therapeutics funds.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs